Variety of qualified clients: CDEC talked about the uncertainty in the amount of people with reasonably severe to significant hemophilia B in Canada suitable for etranacogene dezaparvovec. Scientific authorities consulted by CADTH indicated that some clients that are labeled as owning mild or average illness could have a serious bleeding phenotype,